2026-03-24 20:02:17
Raphael Pharmaceutical Inc. Reports Departure of Board Member in 8-K Filing
Expected Stock impact: None Expected
Raphael Pharmaceutical Inc. has filed an 8-K report with the SEC, disclosing the expiration of Dr. Yehuda Eliya's term as a member of the Board of Directors, effective December 31, 2025. The filing indicates that Dr. Eliya's departure was not due to any disagreements regarding the company's operations, policies, or practices. This administrative update is part of the company's ongoing compliance with SEC regulations. The report does not indicate any immediate impact on the company's operations or governance structure, as it appears to be a routine change in board membership. The company continues to operate under its existing governance framework, and no new appointments have been announced at this time. Investors and stakeholders are encouraged to review the full filing for additional context and details regarding the company's governance.
